Revance Therapeutics (NASDAQ:RVNC) PT Raised to $35.00

Revance Therapeutics (NASDAQ:RVNCGet Rating) had its price objective lifted by equities researchers at Barclays from $22.00 to $35.00 in a report released on Friday, The Fly reports. The firm currently has an “overweight” rating on the biopharmaceutical company’s stock. Barclays‘s target price would suggest a potential upside of 22.94% from the company’s previous close.

A number of other research firms also recently weighed in on RVNC. HC Wainwright boosted their target price on Revance Therapeutics from $25.00 to $29.00 and gave the stock a “buy” rating in a research report on Friday. Needham & Company LLC boosted their target price on Revance Therapeutics from $25.00 to $35.00 and gave the stock a “buy” rating in a research report on Thursday. Cowen boosted their target price on Revance Therapeutics from $55.00 to $65.00 in a research report on Thursday. Wells Fargo & Company boosted their price objective on Revance Therapeutics from $17.00 to $24.00 and gave the company an “equal weight” rating in a research report on Thursday, August 25th. Finally, Guggenheim boosted their price objective on Revance Therapeutics to $35.00 in a research report on Monday, August 15th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, Revance Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $39.75.

Revance Therapeutics Stock Up 12.5 %

Shares of NASDAQ RVNC opened at $28.47 on Friday. The business has a 50-day moving average of $18.59 and a 200-day moving average of $16.76. The firm has a market capitalization of $2.08 billion, a price-to-earnings ratio of -7.39 and a beta of 0.92. Revance Therapeutics has a 12 month low of $11.27 and a 12 month high of $30.00. The company has a current ratio of 3.38, a quick ratio of 3.20 and a debt-to-equity ratio of 14.80.

Revance Therapeutics (NASDAQ:RVNCGet Rating) last released its earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.88) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.91) by $0.03. The company had revenue of $28.37 million during the quarter, compared to the consensus estimate of $27.64 million. Revance Therapeutics had a negative return on equity of 497.77% and a negative net margin of 265.04%. Sell-side analysts expect that Revance Therapeutics will post -3.7 earnings per share for the current fiscal year.

Institutional Trading of Revance Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Principal Financial Group Inc. increased its stake in shares of Revance Therapeutics by 7.6% during the first quarter. Principal Financial Group Inc. now owns 12,850 shares of the biopharmaceutical company’s stock valued at $251,000 after buying an additional 913 shares during the period. Teacher Retirement System of Texas increased its stake in shares of Revance Therapeutics by 7.6% during the first quarter. Teacher Retirement System of Texas now owns 13,921 shares of the biopharmaceutical company’s stock valued at $271,000 after buying an additional 981 shares during the period. Guggenheim Capital LLC increased its stake in shares of Revance Therapeutics by 2.9% during the first quarter. Guggenheim Capital LLC now owns 36,805 shares of the biopharmaceutical company’s stock valued at $718,000 after buying an additional 1,043 shares during the period. Advisor Group Holdings Inc. increased its stake in shares of Revance Therapeutics by 60.6% during the first quarter. Advisor Group Holdings Inc. now owns 2,838 shares of the biopharmaceutical company’s stock valued at $56,000 after buying an additional 1,071 shares during the period. Finally, ProShare Advisors LLC increased its stake in shares of Revance Therapeutics by 4.5% during the fourth quarter. ProShare Advisors LLC now owns 25,425 shares of the biopharmaceutical company’s stock valued at $414,000 after buying an additional 1,085 shares during the period. Institutional investors own 77.08% of the company’s stock.

About Revance Therapeutics

(Get Rating)

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.

Read More

The Fly logo

Analyst Recommendations for Revance Therapeutics (NASDAQ:RVNC)

Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.